Monday, March 22, 2021

Bamlanivimab no longer recommended due to COVID variants in Colorado

The monoclonal antibody bamlanivimab is no longer recommended as monotherapy for the
treatment of COVID-19 in Colorado.

The prevalence of B.1.427/B.1.429 variants is now estimated to be greater than 20% of all
Colorado cases; mutations in these variants are expected to confer resistance to bamlanivimab.

https://drive.google.com/file/d/1AehPczjqZg-Zq_3nv-_2sKMK9Um1TiKj/view?usp=sharing


DS
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)